Insider Buying: Global Medical REIT (NYSE:XRN) Director Acquires $500,920.00 in Stock

Global Medical REIT Inc. (NYSE:XRN) Director Charles Fitzgerald acquired 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was purchased at an average cost of $35.78 per share, with a total value of $500,920.00. Following the acquisition, the director directly owned 138,893 shares of the company’s stock, valued at $4,969,591.54. This trade represents a 11.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Charles Fitzgerald also recently made the following trade(s):

• On Monday, August 10th, Charles Fitzgerald purchased 27,600 shares of Global Medical REIT stock. The shares were purchased at an average price of $35.94 per share, with a total value of $991,944.00.

Global Medical REIT Trading Up 1.9%

Shares of Global Medical REIT stock opened at $37.28 on Friday. The stock has a 50 day moving average of $36.62 and a 200 day moving average of $35.81. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.68 and a current ratio of 0.59. The firm has a market capitalization of $493.59 million, a price-to-earnings ratio of 10.02 and a beta of 1.09. Global Medical REIT Inc. has a fifty-two week low of $29.05 and a fifty-two week high of $39.93.

Global Medical REIT (NYSE:XRN) last posted its earnings results on Wednesday, August 5th. The company reported $4.78 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $3.95. Global Medical REIT had a return on equity of 13.31% and a net margin of 36.82%.The company had revenue of $39.75 million for the quarter. As a group, research analysts predict that Global Medical REIT Inc. will post 2.89 earnings per share for the current year.

Hedge Funds Weigh In On Global Medical REIT

A number of hedge funds have recently modified their holdings of XRN. Marshall Wace LLP raised its position in Global Medical REIT by 0.8% in the 4th quarter. Marshall Wace LLP now owns 38,244 shares of the company’s stock valued at $1,290,000 after purchasing an additional 308 shares during the last quarter. Daiwa Securities Group Inc. grew its position in Global Medical REIT by 7.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 4,827 shares of the company’s stock worth $163,000 after purchasing an additional 332 shares during the last quarter. Fifth Third Bancorp grew its position in Global Medical REIT by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 1,417 shares of the company’s stock worth $48,000 after purchasing an additional 370 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Global Medical REIT by 1,001.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 793 shares of the company’s stock valued at $27,000 after purchasing an additional 721 shares during the period. Finally, Virtus Advisers LLC increased its stake in Global Medical REIT by 46.5% in the fourth quarter. Virtus Advisers LLC now owns 2,418 shares of the company’s stock valued at $82,000 after purchasing an additional 768 shares during the period. 57.52% of the stock is currently owned by hedge funds and other institutional investors.

Key Global Medical REIT News

Here are the key news stories impacting Global Medical REIT this week:

• Positive Sentiment: CEO Mark Okey Decker, Jr. bought 8,000 shares at $35.88 and an additional 6,875 shares at $35.92, while COO Aaron Robert Roseth purchased 13,500 shares at $36.73. Director Charles Fitzgerald also acquired 14,000 shares at $35.78. The reported purchases represent more than $1.5 million of direct insider buying, a potentially bullish signal. Global Medical REIT CEO Purchases Shares
• Positive Sentiment: Global Medical REIT’s latest quarterly results significantly exceeded expectations: earnings per share were $4.78 versus the $0.83 consensus estimate, with revenue of $39.75 million. The company also reported a 36.82% net margin and 13.74% return on equity, providing fundamental support for investor interest.
• Neutral Sentiment: Analyst opinion remains mixed, with two Buy ratings, five Holds and one Sell. The average price target is $40.25, above the recent trading range, but Compass Point maintains a $38 target while Citizens JMP has a $42 target. The overall consensus rating is Hold.
• Neutral Sentiment: Institutional investors own approximately 57.52% of XRN. Recent filings show several funds increasing positions, although the disclosed transactions are not necessarily a near-term catalyst.
• Neutral Sentiment: Coverage also discusses Global Medical REIT’s rebranding and transition to Chiron Real Estate, which may create uncertainty about the company’s identity and strategic direction. Chiron Real Estate rebrand article
• Negative Sentiment: The REIT remains relatively leveraged, with a debt-to-equity ratio of 1.68 and current and quick ratios of 0.68. High debt and limited liquidity could weigh on valuation if interest rates stay elevated or healthcare property conditions weaken.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. BMO Capital Markets boosted their price target on shares of Global Medical REIT from $39.00 to $40.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. Raymond James Financial initiated coverage on Global Medical REIT in a report on Wednesday, June 17th. They set a “market perform” rating for the company. Zacks Research raised Global Medical REIT to a “hold” rating in a research report on Wednesday, July 22nd. Citizens Jmp increased their price objective on Global Medical REIT from $40.00 to $42.00 and gave the company a “market outperform” rating in a report on Tuesday, May 26th. Finally, Compass Point reissued a “neutral” rating and set a $38.00 target price (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $40.25.

Global Medical REIT Company Profile

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.